DCGO — DocGo Inc.

Summary of DocGo Inc. Q4 2025 Earnings Call

1. Key Financial Results and Metrics

• Q4 2025 Revenue: $74.9 million, down from $120.8 million in Q4 2024, primarily due to the wind down of migrant-related projects. Excluding these, revenue increased by 11% year-over-year.
• Full Year 2025 Revenue: $322.2 million, compared to $616.6 million in 2024.
• Adjusted EBITDA: Q4 loss of $11.3 million, compared to a gain of $1.1 million in Q4 2024. Full-year adjusted EBITDA loss was $28.6 million, down from a gain of $60 million in 2024.
• Adjusted Gross Margin: 32.5% in Q4 2025, slightly down from 33.5% in Q4 2024. Medical transportation gross margins improved to 32.8% from 30.1% in 2024.

2. Strategic Updates and Business Highlights

• SteadyMD Performance: Generated $6.1 million in Q4, with full-year patient interactions exceeding 4 million. The integration is on track, aiming for enhanced service delivery by Q2 2026.
• Hiring Improvements: 206 EMT and paramedic roles filled out of 546 open positions, with expectations of reduced overtime costs as staffing stabilizes.
• Mobile Health Growth: Significant increases in various services, including a 113% rise in healthcare-in-the-home visits and a 50% increase in telehealth and lab orders.
• Efficiency Initiatives: Launched a portfolio of projects expected to save $5-$6 million in 2026 and $20-$24 million in 2027, focusing on technology and automation to enhance operational efficiency.

3. Forward Guidance and Outlook

• 2026 Revenue Guidance: Increased to $290 million to $310 million, up from prior guidance of $280 million to $300 million.
• Adjusted EBITDA Guidance: Expected loss revised to $5 million to $10 million, an improvement from the previous range of $15 million to $25 million.
• Gross Margin Expectations: Anticipated blended gross margin for 2026 around 33%, with sequential improvements expected throughout the year.

4. Bad News, Challenges, or Points of Concern

• Cash Position: Year-end cash and cash equivalents decreased to $68.3 million from $95.2 million, primarily due to the acquisition of SteadyMD and delays in collecting $20 million in migrant-related receivables.
• Operational Losses: Continued operating losses are expected in the first half of 2026, creating potential working capital pressures.
• Write-downs: Significant non-cash write-downs of $49.5 million in goodwill and $22.6 million in intangible assets due to market cap discrepancies, which could raise concerns about asset valuations.

5. Notable Q&A Insights

• Strategic Alternatives: The company is exploring strategic alternatives to maximize shareholder value, with an investment bank engaged for the process.
• Revenue Drivers: Increased revenue guidance attributed to higher volumes in medical transportation and SteadyMD's performance, with ongoing focus on staffing improvements.
• Cross-Selling Opportunities: Emphasis on leveraging care gap closure services to promote additional offerings like remote patient monitoring and primary care, indicating potential for future growth.
• Cash Flow Management: Ongoing discussions with credit line providers regarding financial covenants, with expectations of maintaining access to credit despite current EBITDA losses.

Overall, while DocGo Inc. reported a challenging year with significant revenue declines and operational losses, there are positive signs of growth in specific segments, particularly in mobile health and virtual care, alongside strategic initiatives aimed at improving efficiency and profitability.